Podcast: Play in new window | Download (Duration: 12:20 — 17.5MB) | Embed
Dapagliflozin is an SGLT-2 Inhibitor that reduces blood sugar by increasing the excretion of sugar through the urine.
Genital and urinary infections is a potential risk with the use of SGLT2 Inhibitors like dapagliflozin.
Dapagliflozin has received FDA approval for use in heart failure (in patients even without diabetes).
Be aware of agents that may enhance the risk for hypoglycemia such an insulin and sulfonylureas.
I discuss important drug interactions on the podcast, be sure to check out my latest project which is a 200+ page book on managing drug interactions in primary care.
Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE!